title: Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation.
abstract: In all, 41 multiple myeloma (MM) patients received an antithymocyte globulin (ATG), fludarabine, and busulfan-based reduced intensity conditioning (RIC) for allogeneic stem cell transplantation (allo-SCT) from HLA-identical siblings. In total, 29 patients (70%) were in partial remission, one patient in complete remission, and 11 (27%) with progressive disease at the time of allo-SCT. Median time between diagnosis and allo-SCT was 24 months. The cumulative incidences of grade II-IV and grade III-IV acute graft-versus-host disease (GVHD) were 36% (95% CI, 21-51%) and 7% (95% CI, 2-20%), respectively. Overall, 10 patients developed limited chronic GVHD, whereas seven developed an extensive form (cumulative incidence, 41% (95% CI, 26-56%) at 2 years). With a median follow-up of 389 days, the overall cumulative incidence of transplant-related mortality (TRM) was 17% (95% CI, 6-28%). In all, 11 patients (27%) are in continuous complete remission, and the Kaplan-Meier estimates of overall survival (OS) and progression-free survival (PFS) at 2 years were 62% (95% CI, 47-76%) and 41% (95% CI, 23-62%), respectively. PFS and OS were significantly higher in patients with chronic GVHD as compared to patients without chronic GVHD (P=0.006 for PFS and P=0.01 for OS). Collectively, these data demonstrate that RIC allo-SCT can mediate a potentially curative graft-versus-myeloma effect with an acceptable incidence of toxicity and TRM.
authors.affiliation: Unité de Transplantation et de Thérapie Cellulaire, Institut Paoli-Calmettes, Marseille, France. mohtym@marseille.fnclcc.fr
authors.forename: M
authors.initials: M
authors.lastname: Mohty
authors.forename: J M
authors.initials: JM
authors.lastname: Boiron
authors.forename: G
authors.initials: G
authors.lastname: Damaj
authors.forename: A S
authors.initials: AS
authors.lastname: Michallet
authors.forename: J O
authors.initials: JO
authors.lastname: Bay
authors.forename: C
authors.initials: C
authors.lastname: Faucher
authors.forename: V
authors.initials: V
authors.lastname: Perreau
authors.forename: K
authors.initials: K
authors.lastname: Bilger
authors.forename: D
authors.initials: D
authors.lastname: Coso
authors.forename: A M
authors.initials: AM
authors.lastname: Stoppa
authors.forename: R
authors.initials: R
authors.lastname: Tabrizi
authors.forename: J A
authors.initials: JA
authors.lastname: Gastaut
authors.forename: M
authors.initials: M
authors.lastname: Michallet
authors.forename: D
authors.initials: D
authors.lastname: Maraninchi
authors.forename: D
authors.initials: D
authors.lastname: Blaise
mesh_terms: D000328:Adult; D000961:Antilymphocyte Serum / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D002066:Busulfan / Q000009:adverse effects; D005260:Female; D006086:Graft vs Host Disease; D020350:Graft vs Tumor Effect / Q000187:drug effects*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods* / Q000401:mortality; D006801:Humans; D015994:Incidence; D017710:Lymphocyte Transfusion; D008297:Male; D008875:Middle Aged; D016019:Survival Analysis; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D000961:Antilymphocyte Serum; D014740:Vidarabine; D002066:Busulfan; C024352:fludarabine